04/26/2024
7:30 AM | Viridian Therapeutics, Inc.\DE (Filer)
Viridian Therapeutics (Filer)
| Form DEF 14A | |
04/26/2024
7:30 AM | Viridian Therapeutics, Inc.\DE (Filer)
Viridian Therapeutics (Filer)
| Form DEF 14A | |
04/26/2024
7:32 AM | Viridian Therapeutics, Inc.\DE (Filer)
Viridian Therapeutics (Filer)
| Form DEFA14A | |
04/26/2024
7:32 AM | Viridian Therapeutics, Inc.\DE (Filer)
Viridian Therapeutics (Filer)
| Form DEFA14A | |
04/26/2024
7:34 AM | Viridian Therapeutics, Inc.\DE (Filer)
Viridian Therapeutics (Filer)
| Form ARS | |
04/26/2024
7:34 AM | Viridian Therapeutics, Inc.\DE (Filer)
Viridian Therapeutics (Filer)
| Form ARS | |
04/01/2024
5:38 PM | Fairmount Funds Management LLC (Filed by)
Viridian Therapeutics, Inc.\DE (Subject)
Viridian Therapeutics (Subject)
| Form SC 13D/A | |
|
04/01/2024
5:32 PM | Fairmount Funds Management LLC (Reporting)
Fairmount Healthcare Fund GP LLC (Reporting)
Fairmount Healthcare Fund II GP LLC (Reporting)
Fairmount Healthcare Fund II L.P. (Reporting)
Fairmount Healthcare Fund L.P. (Reporting)
Viridian Therapeutics, Inc.\DE (Issuer)
Viridian Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/27/2024
3:34 PM | Viridian Therapeutics, Inc.\DE (Filer)
Viridian Therapeutics (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
02/14/2024
7:28 PM | Venrock Healthcare Capital Partners III, L.P. (Filed by)
Viridian Therapeutics, Inc.\DE (Subject)
Viridian Therapeutics (Subject)
| Form SC 13G/A | |
02/14/2024
8:22 AM | BIOTECHNOLOGY VALUE FUND L P (Filed by)
Viridian Therapeutics, Inc.\DE (Subject)
Viridian Therapeutics (Subject)
| Form SC 13G/A | |
01/29/2024
3:53 PM | PERCEPTIVE ADVISORS LLC (Filed by)
Viridian Therapeutics, Inc.\DE (Subject)
Viridian Therapeutics (Subject)
| Form SC 13G | |
01/29/2024
2:26 PM | BlackRock Inc. (Filed by)
Viridian Therapeutics, Inc.\DE (Subject)
Viridian Therapeutics (Subject)
| Form SC 13G/A | |
01/24/2024
5:44 PM | Fairmount Funds Management LLC (Reporting)
Fairmount Healthcare Fund GP LLC (Reporting)
Fairmount Healthcare Fund II GP LLC (Reporting)
Fairmount Healthcare Fund II L.P. (Reporting)
Fairmount Healthcare Fund L.P. (Reporting)
Viridian Therapeutics, Inc.\DE (Issuer)
Viridian Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/24/2024
7:13 AM | STATE STREET CORP (Filed by)
Viridian Therapeutics, Inc.\DE (Subject)
Viridian Therapeutics (Subject)
| Form SC 13G | |
01/19/2024
4:22 PM | Viridian Therapeutics, Inc.\DE (Filer)
Viridian Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/19/2024
3:32 PM | Viridian Therapeutics, Inc.\DE (Filer)
Viridian Therapeutics (Filer)
| Form 424B5 | |
01/12/2024
3:31 PM | Ciulla Thomas (Reporting)
Viridian Therapeutics, Inc.\DE (Issuer)
Viridian Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
01/10/2024
7:53 AM | FMR LLC (Filed by)
Viridian Therapeutics, Inc.\DE (Subject)
Viridian Therapeutics (Subject)
| Form SC 13G | |
01/08/2024
7:08 AM | Viridian Therapeutics, Inc.\DE (Filer)
Viridian Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/18/2023
10:45 AM | Meisner Lara (Reporting)
Viridian Therapeutics, Inc.\DE (Subject)
Viridian Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/18/2023
7:15 AM | Viridian Therapeutics, Inc.\DE (Filer)
Viridian Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/12/2023
3:19 PM | Humer Kristian (Reporting)
Viridian Therapeutics, Inc.\DE (Subject)
Viridian Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/08/2023
3:17 PM | Venrock Opportunities Fund, L.P. (Filed by)
Viridian Therapeutics, Inc.\DE (Subject)
Viridian Therapeutics (Subject)
| Form SC 13G | |
12/07/2023
3:22 PM | Humer Kristian (Reporting)
Viridian Therapeutics, Inc.\DE (Subject)
Viridian Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/01/2023
3:04 PM | Meisner Lara (Reporting)
Viridian Therapeutics, Inc.\DE (Subject)
Viridian Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/13/2023
4:17 PM | Harmon Seth (Reporting)
Viridian Therapeutics, Inc.\DE (Issuer)
Viridian Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/03/2023
3:30 PM | Fairmount Funds Management LLC (Filed by)
Viridian Therapeutics, Inc.\DE (Subject)
Viridian Therapeutics (Subject)
| Form SC 13D/A | |
11/02/2023
3:31 PM | Viridian Therapeutics, Inc.\DE (Filer)
Viridian Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/01/2023
8:05 PM | Fairmount Funds Management LLC (Reporting)
Fairmount Healthcare Fund GP LLC (Reporting)
Fairmount Healthcare Fund II GP LLC (Reporting)
Fairmount Healthcare Fund II L.P. (Reporting)
Fairmount Healthcare Fund L.P. (Reporting)
Viridian Therapeutics, Inc.\DE (Issuer)
Viridian Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/01/2023
3:35 PM | Mahoney Stephen F. (Reporting)
Viridian Therapeutics, Inc.\DE (Issuer)
Viridian Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/01/2023
3:35 PM | Beetham Thomas W. (Reporting)
Viridian Therapeutics, Inc.\DE (Issuer)
Viridian Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/01/2023
3:40 PM | Beetham Thomas W. (Reporting)
Viridian Therapeutics, Inc.\DE (Issuer)
Viridian Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
11/01/2023
3:30 PM | Mahoney Stephen F. (Reporting)
Viridian Therapeutics, Inc.\DE (Issuer)
Viridian Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
10/30/2023
7:35 AM | Viridian Therapeutics, Inc.\DE (Filer)
Viridian Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
09/25/2023
3:30 PM | Gheuens Sarah (Reporting)
Viridian Therapeutics, Inc.\DE (Issuer)
Viridian Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
09/25/2023
3:35 PM | Gheuens Sarah (Reporting)
Viridian Therapeutics, Inc.\DE (Issuer)
Viridian Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/25/2023
7:00 AM | Viridian Therapeutics, Inc.\DE (Filer)
Viridian Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
09/19/2023
3:30 PM | Harmon Seth (Reporting)
Viridian Therapeutics, Inc.\DE (Issuer)
Viridian Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
08/08/2023
4:21 PM | Viridian Therapeutics, Inc.\DE (Filer)
Viridian Therapeutics (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
07/24/2023
3:06 PM | Viridian Therapeutics, Inc.\DE (Filer)
Viridian Therapeutics (Filer)
| Form S-3ASR | |
Better than Bitcoin? The Biotech Stock with 46,751% Potential (Ad) 4x Better than Bitcoin
Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December. Get the name of the stock here >>> |
07/17/2023
6:06 AM | Viridian Therapeutics, Inc.\DE (Filer)
Viridian Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/10/2023
4:13 PM | Viridian Therapeutics, Inc.\DE (Filer)
Viridian Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/20/2023
4:23 PM | Meisner Lara (Reporting)
Viridian Therapeutics, Inc.\DE (Issuer)
Viridian Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/16/2023
6:51 PM | Morris Arlene (Reporting)
Viridian Therapeutics, Inc.\DE (Issuer)
Viridian Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/16/2023
6:54 PM | Kiselak Tomas (Reporting)
Viridian Therapeutics, Inc.\DE (Issuer)
Viridian Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/16/2023
6:54 PM | Moses Jennifer K. (Reporting)
Viridian Therapeutics, Inc.\DE (Issuer)
Viridian Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/16/2023
7:00 PM | Harwin Peter Evan (Reporting)
Viridian Therapeutics, Inc.\DE (Issuer)
Viridian Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/16/2023
3:31 PM | Viridian Therapeutics, Inc.\DE (Filer)
Viridian Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/14/2023
3:15 PM | Atlas Venture Fund VII L P (Filed by)
Viridian Therapeutics, Inc.\DE (Subject)
Viridian Therapeutics (Subject)
| Form SC 13D/A | |
06/06/2023
6:41 PM | Meisner Lara (Reporting)
Viridian Therapeutics, Inc.\DE (Issuer)
Viridian Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/10/2023
5:36 AM | Viridian Therapeutics, Inc.\DE (Filer)
Viridian Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
04/28/2023
7:28 AM | Viridian Therapeutics, Inc.\DE (Filer)
Viridian Therapeutics (Filer)
| Form ARS | |
04/28/2023
7:27 AM | Viridian Therapeutics, Inc.\DE (Filer)
Viridian Therapeutics (Filer)
| Form DEFA14A | |
04/28/2023
7:24 AM | Viridian Therapeutics, Inc.\DE (Filer)
Viridian Therapeutics (Filer)
| Form DEF 14A | |
